Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Tentative ANDA Approval
Orbicular and its U.S. front‑end partner secured tentative FDA ANDA approval for a generic Ozempic (semaglutide injection); OneSource acted as CDMO supporting development and commercial supply from its US‑FDA approved Bangalore site.
Regulatory Approval
Orbicular (with its U.S. ANDA holder) secured tentative FDA approval for a generic Ozempic (semaglutide) injection, with OneSource acting as CDMO providing end-to-end manufacturing from its US‑FDA approved Bangalore site.
Certification Renewal
OneSource Specialty Pharma’s Flagship Unit II in Bengaluru has received renewal of its EU-GMP certification following inspection by a European regulator, confirming compliance for biologics, sterile injectables and drug‑device manufacturing.
OneSource Specialty Pharma Ltd (ONESOURCE) is currently trading at 1,699.20 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Onesource Specialty Pharma Limited is a CDMO focused on biologics and injectables, offering end-to-end services for drug development and manufacturing. The company's Q3FY26 performance was impacted by customer approval delays, but it maintains strong business fundamentals with an upward trending order book. Despite a revenue decline of 26% YoY, Onesource continues to expand its biosimilar funnel, securing over 10 projects and onboarding new global customers. Onesource has committed to a $75m investment in capacity expansion, driven by high demand in the GLP-1 segment, and plans further growth through strategic initiatives. The company is recognized for its sustainability practices, improving its EcoVadis score and receiving multiple awards for safety and environmental initiatives.
Over the past 52 weeks, OneSource Specialty Pharma Ltd has traded between a low of ₹1,075.00 and a high of ₹2,249.65. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
OneSource Specialty Pharma Ltd has a market capitalization of approximately 18,464.33. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
OneSource Specialty Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 812.30 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 18,464.33 Cr, OneSource Specialty Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
OneSource Specialty Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of OneSource Specialty Pharma Ltd is 812.30. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The 10,000 crore scheme supports the domestic production of biologics and biosimilars, which are core growth areas for OneSource's CDMO business.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
146.10 | 20,457 Cr | -117.53 | 2.53 | 0.09 | -0.29 | 4.50 | -1.01 | ||
2208.90 | 19,833 Cr | 70.73 | 14.03 | 0.06 | 15.84 | 21.30 | 16.80 | ||
13047.00 | 19,346 Cr | 93.45 | 11.95 | 0.08 | 12.09 | 14.48 | 7.07 | ||
1027.85 | 19,183 Cr | 11.82 | 2.22 | 0.56 | 17.79 | 21.15 | 14.81 | ||
1344.50 | 18,721 Cr | 43.21 | 5.33 | 0.53 | 13.45 | 14.38 | 6.57 | ||
1403.95 | 18,464 Cr | 812.30 | 3.13 | 0.00 | 2.34 | 3.64 | 0.25 | ||
645.35 | 16,680 Cr | 29.32 | 3.89 | 0.22 | 12.88 | 13.37 | 7.86 | ||
| Median: 7 Co. | — | 1344.50 | 19,183 Cr | 43.21 | 3.89 | 0.09 | 12.88 | 14.38 | 7.07 |
Bearish
8
Neutral
1
Bullish
5
Bearish
8
Neutral
1
Bullish
37
Bearish
0
Neutral
0
Bullish
32
Onesource Specialty Pharma Limited is a CDMO focused on biologics and injectables, offering end-to-end services for drug development and manufacturing.
The company's Q3FY26 performance was impacted by customer approval delays, but it maintains strong business fundamentals with an upward trending order book.
Despite a revenue decline of 26% YoY, Onesource continues to expand its biosimilar funnel, securing over 10 projects and onboarding new global customers.
Onesource has committed to a $75m investment in capacity expansion, driven by high demand in the GLP-1 segment, and plans further growth through strategic initiatives.
The company is recognized for its sustainability practices, improving its EcoVadis score and receiving multiple awards for safety and environmental initiatives.
Pharmaceuticals & Biotechnology
Pharmaceuticals
18,464 Cr
Low Risk
812.3
32.3
1.4
3.1
2,249.65
1,075.00
Sales CAGR
Profit CAGR
ROE
ROCE
